VRAX (VRAX) Stock Price & Analysis
VRAX (VRAX) rose 0.00% to USD 3.19 as of July 25, 2026 at 07:12 UTC, according to Nexqual real-time market data.
VRAX last closed at USD 3.19; the session ranged USD 3.11–3.19 on volume of 83,739 shares. Market capitalization is $2.54M, with a 52-week range of USD 2.5–25.75 (NCM). Source: Nexqual, July 25, 2026 at 07:12 UTC.
Key Statistics (as of July 25, 2026 at 07:12 UTC)
| Price | USD 3.19 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 3.19 |
| Open | USD 3.17 |
| Day Range | USD 3.11 – 3.19 |
| 52-Week Range | USD 2.5 – 25.75 |
| Volume | 83,739 shares |
| Market Cap | $2.54M |
| Exchange | NCM |
Technical Analysis (VRAX)
Nexqual's technical model rates VRAX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 07:12 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.46 (neutral) |
| vs SMA50 | Below (USD 4.42) |
| MACD | -0.18 (negative) |
Analyst Ratings (VRAX)
Wall Street analysts rate VRAX "None" based on 1 analysts, with a mean price target of USD 25 (range USD 25–25), per Nexqual as of July 25, 2026 at 07:12 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 25 |
| High Target | USD 25 |
| Low Target | USD 25 |
Earnings (VRAX)
| EPS Estimate | USD -1.75 |
|---|
Source: Nexqual, July 25, 2026 at 07:12 UTC.
Financials & Fundamentals (VRAX)
| Total Revenue | $12,423 |
|---|---|
| Revenue Growth (YoY) | +684.90% |
| Gross Margin | +61.90% |
| Operating Margin | -35264.92% |
| Profit Margin | +0.00% |
| ROE | -78.65% |
| Debt / Equity | 5.65 |
| Current Ratio | 9.97 |
| Total Cash | $6.52M |
| Total Debt | $414,387 |
| Free Cash Flow | $-3.48M |
Source: Nexqual, July 25, 2026 at 07:12 UTC.
Financial Health Score (VRAX)
Nexqual rates VRAX's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 07:12 UTC.
| Growth | Strong — Revenue +96% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $7M cash, no debt |
| Cash Flow | Weak — FCF negative: -$3M, burning cash |
| Efficiency | Critical — ROE -79%, ROA -54.2% |
Ownership (VRAX)
| Insider Ownership | +2.62% |
|---|---|
| Institutional Ownership | +4.61% |
| Shares Outstanding | 796,988 |
| Float | 529,035 |
| Short % of Float | +3.23% |
Source: Nexqual, July 25, 2026 at 07:12 UTC.
Leadership (VRAX)
VRAX is led by James Foster (age 40), Chairman, CEO & Principal Accounting Officer, per Nexqual as of July 25, 2026 at 07:12 UTC.
| Chairman, CEO & Principal Accounting Officer | James Foster (age 40) |
|---|---|
| COO & Director | Nigel McCracken M.Sc. (age 60) |
Major Backers & Investors (VRAX)
Notable institutional backers of VRAX include Armistice Capital, LLC, Jump Financial, LLC, according to Nexqual as of July 25, 2026 at 07:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 4.41% |
| Jump Financial, LLC | 0.2% |
Source: Nexqual, July 25, 2026 at 07:12 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 4.28 | ▼ 2.17% |
| REVB | Revelation Biosciences, Inc. | USD 1.06 | ▼ 7.83% |
| SOBR | SOBR Safe, Inc. | USD 0.6 | ▲ 3.01% |
| ILAG | Intelligent Living Application | USD 3.45 | ▼ 0.23% |
| AKAN | Akanda Corp. | USD 7.73 | ▼ 4.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:12 UTC. This page is informational and not investment advice.